...
首页> 外文期刊>Clinical and Experimental Metastasis >Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance
【24h】

Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance

机译:肝细胞诱导的乳腺癌和前列腺癌细胞中E-钙黏着蛋白的重新表达增加化学耐药性

获取原文

摘要

Post-extravasation survival is a key rate-limiting step of metastasis; however, not much is known about the factors that enable survival of the metastatic cancer cell at the secondary site. Furthermore, metastatic nodules are often refractory to current therapies, necessitating the elucidation of molecular changes that affect the chemosensitivity of metastases. Drug resistance exhibited by tumor spheroids has been shown to be mediated by cell adhesion and can be abrogated by addition of E-cadherin blocking antibody. We have previously shown that hepatocyte coculture induces the re-expression of E-cadherin in breast and prostate cancer cells. In this study, we show that this E-cadherin re-expression confers a survival advantage, particularly in the liver microenvironment. E-cadherin re-expression in MDA-MB-231 breast cancer cells resulted in increased attachment to hepatocytes. This heterotypic adhesion between cancer cells and secondary organ parenchymal cells activated ERK MAP kinase, suggesting a functional pro-survival role for E-cadherin during metastatic colonization of the liver. In addition, breast cancer cells that re-expressed E-cadherin in hepatocyte coculture were more chemoresistant compared to 231-shEcad cells unable to re-express E-cadherin. Similar results were obtained in DU-145 prostate cancer cells induced to re-express E-cadherin in hepatocyte coculture or following chemical induction by the GnRH agonist buserelin or the EGFR inhibitor PD153035. These results suggest that E-cadherin re-expression and other molecular changes imparted by a partial mesenchymal to epithelial reverting transition at the secondary site increase post-extravasation survival of the metastatic cancer cell and may help to elucidate why chemotherapy commonly fails to treat metastatic breast cancer.
机译:外渗后存活是转移的关键速率限制步骤。然而,关于使转移癌细胞在继发部位存活的因素知之甚少。此外,转移性结节通常对目前的治疗无效,因此必须阐明影响转移化学敏感性的分子变化。肿瘤球体所表现出的耐药性已被证明是由细胞粘附介导的,并且可以通过添加E-钙粘着蛋白阻断抗体来消除。先前我们已经表明,肝细胞共培养可诱导乳腺癌和前列腺癌细胞中E-钙粘着蛋白的重新表达。在这项研究中,我们表明,这种E-钙粘着蛋白的重新表达赋予了生存优势,尤其是在肝脏微环境中。 E-钙黏着蛋白在MDA-MB-231乳腺癌细胞中的重新表达导致与肝细胞的附着增加。癌细胞和次要器官实质细胞之间的这种异型粘附激活了ERK MAP激酶,表明E-钙粘着蛋白在肝脏转移性定植过程中具有功能性的生存前作用。此外,与无法重新表达E-钙粘蛋白的231-shEcad细胞相比,在肝细胞共培养物中重新表达E-钙粘蛋白的乳腺癌细胞具有更高的化学耐药性。在被诱导在肝细胞共培养物中重新表达E-钙粘着蛋白的DU-145前列腺癌细胞中,或在GnRH激动剂buserelin或EGFR抑制剂PD153035的化学诱导后,得到了类似的结果。这些结果表明,E-钙粘蛋白的二次表达和其他分子变化(在次级部位由间质向上皮的回复转变)赋予了转移癌细胞大量的浸润后生存期,并可能有助于阐明为什么化学疗法通常不能治疗转移性乳腺癌癌症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号